Incidence of DR at Each Landmark Time Assessment in OPTiM Patients Treated with Talimogene Laherparepvec and GM-CSFa
| Landmark Time, Months | Patients Alive, n | DR Achieved, n | HR for OS in Patients with DR Versus Those Without, HR (95% CI) | Adjusted HR for OS in Patients with DR Versus Those Without HR (95% CI)b |
|---|---|---|---|---|
| 9 | 335 | 22 | 0.07 (0.01–0.48) | 0.07 (0.01–0.54) |
| 12 | 304 | 36 | 0.05 (0.01–0.33) | 0.05 (0.01–0.35) |
| 18 | 236 | 50 | 0.11 (0.03–0.44) | 0.11 (0.03–0.47) |
DR durable response, GM-CSF granulocyte macrophage-colony stimulating factor, HR hazard ratio, ITT intent-to-treat, OS overall survival
aAnalysis was performed in ITT population of OPTiM
bAdjusted for disease stage (stage IIIB, IIIC, IVM1a versus stage IVM1b, IVM1c) and line of therapy (first-line versus second-line)